IAS 2023

Highlights from the 12th IAS Conference on HIV Science, held July 23-26, 2023.

No change in body weight with switching antiretroviral regimens in those who experience weight gain on integrase inhibitors

Presenter: William Short, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia

A prospective, randomized trial to assess a protease inhibitor-based regimen switch strategy to manage integrase inhibitor-related weight gain. Presented July 25,2023.

Rapid initiation of ART soon after HIV diagnosis increases number of people starting ART and is cost-effective

Presenter: Starley Shade, PhD University of California, San Francisco.

Costs and cost-effectiveness of immediate initiation of antiretroviral therapy upon diagnosis of HIV (Rapid Start) in the United States. Presented July 24, 2023.

Daily statin is game changer for heart disease prevention in people living with HIV

Presenter: Steven Grinspoon, MD, Harvard Medical School, Boston

Key REPRIEVE results and the utility of statins among people living with HIV: what have we learned. Presented July 24, 2023.

Resistance to dolutegravir as part of optimized background therapy is common in HIV-1-infected children but is not associated with virologic failure

Presenter: Ceejay Boyce, PhD, Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle.a

Prevalence and dynamics of drug resistance during dolutegravir-containing treatment in a pediatric population living with HIV-1 (IMPAACT P1093). Presented July 24, 2023.

Virologic suppression maintained through pregnancy and postpartum with B/F/TAF

Presenter: Dhananjay Marathe, PhD, Gilead Sciences, Foster City, Calif.

Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV. Presented July 24, 2023.

Real-world data in a low-resource region show high treatment persistence and sustained virologic suppression with fixed-dose B/F/TAF

Presenter: Diego Martín Cecchini, MD, PhD, Helios Salud, Buenos Aires, Argentina

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination for the treatment of people living with HIV in Argentina: first interim report of the BICTARG cohort.

Prevalence of drug-drug interactions has decreased in the INSTI era but is still substantial

Presenter: An-Ting Peng, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan, Republic of China

Lower prevalence of potential drug-drug interactions among people living with HIV in the era of integrase inhibitor-based antiretroviral therapy.

Rates of sustained viral suppression are similar between single-tablet bictegravir/emtricitabine/tenofovir alafenamide and two-tablet dolutegravir plus emtricitabine/tenofovir disoproxil fumarate in people with HIV-1 and HBV coinfection

Presenter: Anchalee Avihingsanon, MD, HIV-NAT, Thai Red Cross AIDS Research Centre and Centre of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Week-96 results of ALLIANCE, a phase 3, randomized, double-blind study comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in treatment-naïve people with both HIV-1 and hepatitis B.

Accelerated epigenetic aging persists in adolescents with perinatally acquired HIV

Presenter: Sarah Heany, PhD, University of Cape Town, Psychiatry and Mental Health, Cape Town, South Africa

Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically acquired HIV-positive adolescents.